CD8A and intrahepatic cholangiocarcinoma: A similar observation was previously reported for patients with intrahepatic cholangiocarcinoma receiving combined therapy with ICIs, where such a transition from CD8 GZMB+ to CD8 GZMK+ facilitated good response to therapy.47